Shen J, Yang R H, Zhang Y C, Liao A J, Liu Z G, Yang W
Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Department of Blood Transfusion, China Medical University First Hospital, Shenyang 110001, China.
Zhonghua Xue Ye Xue Za Zhi. 2020 Aug 14;41(8):675-679. doi: 10.3760/cma.j.issn.0253-2727.2020.08.011.
In this study, we aimed to determine the change and clinical significance of serum level Apo A1 in MM patients. In total, 412 multiple myeloma patients were examined. SPSS 22.0 was used for data analysis. Correlation analysis was performed using linear correlation or Spearman rank correlation coefficients. Measurement data were analyzed with the t-test, Mann-Whitney U-test, or oneway analysis of variance (ANOVA) . Used the ROC curve to calculate the cutoff value and compared the OS and PFS between high Apo A1 subgroup and low Apo A1 subgroup with Kaplan-Meier survival analysis. Our study showed that value of Apo A1 in the patient group was lower than that in the control group (0.89 g/L 1.24 g/L, <0.05) . We found that Apo A1 dynamically changed with different MM stages. As it was increased when the disease was in remission, and decreased after disease in progression. According the result of multivariate analysis Apo A1 reduction become the independent risk factors of MM. On the basis of Kaplan-Meier survival analysis between high Apo A1 subgroup and low Apo A1 subgroup, we found higher Apo A1 patienta had longer OS rate and PFS. Apo A1 is a useful biomarker of tumor burden and a prognostic factor of multiple myeloma.
在本研究中，我们旨在确定骨髓瘤患者血清载脂蛋白A1（Apo A1）水平的变化及其临床意义。总共对412例多发性骨髓瘤患者进行了检查。使用SPSS 22.0进行数据分析。采用线性相关或Spearman等级相关系数进行相关性分析。计量资料采用t检验、Mann-Whitney U检验或单因素方差分析（ANOVA）。利用ROC曲线计算临界值，并采用Kaplan-Meier生存分析比较高Apo A1亚组和低Apo A1亚组之间的总生存期（OS）和无进展生存期（PFS）。我们的研究表明，患者组的Apo A1值低于对照组（0.89 g/L对1.24 g/L，P<0.05）。我们发现Apo A1随骨髓瘤不同分期动态变化。疾病缓解时升高，疾病进展后降低。多因素分析结果显示，Apo A1降低成为骨髓瘤的独立危险因素。基于高Apo A1亚组和低Apo A1亚组之间的Kaplan-Meier生存分析，我们发现Apo A1水平较高的患者OS率和PFS更长。Apo A1是肿瘤负荷的有用生物标志物和多发性骨髓瘤的预后因素。
